Dysmenorrhea
Conditions
Interventions
Tranilast administration of between 6 months
placebo administration of between 6 months
Sponsors
Endometriosis / Tranilast Study Group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) age is less than 45 years of age or 20 years of age at the time of obtaining informed consent, menstrual cycle is 25-38 days patients (2) patients with dysmenorrhea VAS is greater than or equal to 30mm (3) patients symptoms of dysmenorrhea has been controlled by only the use of N-saids, which has been determined to be controlled by only N-Saids throughout the study period (4) patients who do not wish to become pregnant during the study period (5) for participation in the study, patients consent document person was obtained
Exclusion criteria
Exclusion criteria: (1) age is less than 45 years of age or 20 years of age at the time of obtaining informed consent, menstrual cycle is 25-38 days patients (2) patients with dysmenorrhea VAS is greater than or equal to 30mm (3) patients symptoms of dysmenorrhea has been controlled by only the use of N-saids, which has been determined to be controlled by only N-Saids throughout the study period (4) patients who do not wish to become pregnant during the study period (5) for participation in the study, patients consent document person was obtained
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS of dysmenorrhea | — |
Secondary
| Measure | Time frame |
|---|---|
| Dysmenorrhea score Lower abdominal pain during menstruation, low back pain, headache, degree of nausea Other than during menstruation pelvic pain VAS Serum CA125 concentration TTF (Time to Treatment Failure) (such as incidence of adverse events) | — |
Countries
Japan
Contacts
Public ContactRitsuo Honda
Kumamoto University Hospital Department of Obstetrics and Gynecology
Outcome results
None listed